(7.3 months for the PPP cohort) and was longer than the median rwPFS reported from studies of patients with NSCLC and EGFR ex20ins mutations receiving other EGFR TKIs (1.4–3.0 months; eight studies [183 patients]) [6]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.